|
Mutation Information
|
Mutation Site
|
G163R |
|
Mutation Type
|
Amino acid level |
|
Gene/Protein/Region Type
|
IN |
|
Relevant Drug
|
INSTIs |
|
Country
|
UK |
Literature Information
|
PubMed PMID
|
30409215
|
|
Clinical information
|
Yes
|
|
Disease
|
HIV infection/AIDS
|
|
Published Year
|
2018 |
|
Journal
|
AIDS research and therapy |
|
Title
|
Characterization of minority HIV-1 drug resistant variants in the United Kingdom following the verification of a deep sequencing-based HIV-1 genotyping and tropism assay. |
|
Author
|
Silver N,Paynter M,McAllister G,Atchley M,Sayir C,Short J,Winner D,Alouani DJ,Sharkey FH,Bergefall K,Templeton K,Carrington D,Quiñones-Mateu ME |
|
Evidence
|
Most of these minority drug resistance mutations were detected in the 67 cART-experienced individuals, e.g., the HIV-1 genotype of the following patients consisted of a mixture of majority and minority drug resistance mutations: patient SG79 (PR V11I 99.9%, K20I 99.9%;RT E44D 1.3%, D67N 1.1%, L100I 1.7%, M184V 84.9%, M184I 14.8%, K219Q 2.1%, INT E157Q 99.8%), patient SG86 (RT M184V 99.8%, INT L74M 97.9%, L74I 1.9%, E92Q 86.1%, E92V 7.4%, T97A 99.8%, G163R 1.1%), patient NHS49 (PR E35G 1.3%, M46L 3.1%, I50 V 2.5%, F53L 1.4%, RT M41L 99.2%, D67N 2.3%, M184V 15.4%, T215Y 99.1%) and patient NHS72 (PR M46L 1.1%, RT D67N 1.4%, K103R 99.6%, M184V 99.8%, Y188C 19.3%, INT T66I 99.8%, L74I 99.8%, T97A 98.8%, E157Q 8.7%).
|
|
|
HIV Mutation Detail Information